salivary duct carcinoma salivary gland cancer
Conditions
Interventions
None listed
Sponsors
Radboud Universitair Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: • Patients must have the ability to provide written informed consent. • Patients must be >= 18 years of age. • Patients must have histological, pathological, and/or cytological confirmation of salivary duct carcinoma, androgen receptor positive. • Only patients with locally advanced, recurrent or metastatic salivary duct carcinoma can participate. • Patients must have at least one lesion with a diameter of >= 1.5 cm. • Patients whom intend to start androgen deprivation therapy, after this has been re-commended by the treating physician as standard treatment.
Exclusion criteria
Exclusion criteria: • Contra-indication for PET imaging: pregnancy or breast feeding or severe claustrophobia • Impaired renal function: MDRD <30 ml/min/1,73 m2 • Impaired liver function: AST and ALT ALT >= 2.5 x ULN (>=5 x ULN for patients with liver metastases)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The percentage of patients with an ADT induced increase in PSMA ligand uptake on 68Ga-PSMA-PET/CT. | — |
Secondary
| Measure | Time frame |
|---|---|
| - standardised uptake values (SUV) of recurrence and/or metastases in 68Ga-PSMA-PET/CT pre- and post ADT. - standardised uptake values of recurrence and/or metastases in 18FDG-PET/CT pre- and post ADT. - correlation between SUV and the degree of immunohistochemical PSMA expression. | — |
Countries
Netherlands
Outcome results
None listed